Loading...
•
Jun 30
AbbVie Q2 2025 Earnings Report
AbbVie reported its second-quarter 2025 financial results.
Key Takeaways
AbbVie delivered solid results in Q2 2025 with revenue growth driven by its immunology and neuroscience portfolios, despite ongoing declines in Humira sales and aesthetics.
Total net revenue reached $15.423 billion, up from $14.462 billion in Q2 2024.
Adjusted EPS rose to $2.97 while GAAP EPS was $0.52 due to milestone expenses.
Immunology was the top-performing segment with $7.631 billion in revenue.
Skyrizi and Rinvoq significantly offset Humira’s revenue decline.
AbbVie
AbbVie
AbbVie Revenue by Segment
AbbVie Revenue by Geographic Location
Revenue by Segment
Immunology Revenue
CapyFin.comNeuroscience Revenue
CapyFin.comOncology Revenue
CapyFin.comAesthetics Revenue
CapyFin.comEye Care Revenue
CapyFin.comOther Key Products Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
AbbVie raised its full-year 2025 adjusted EPS guidance to $11.88 - $12.08.
Positive Outlook
- Raised full-year 2025 adjusted EPS guidance.
- Strong performance from Skyrizi and Rinvoq.
- Improved clinical data across several pipeline programs.
- Regulatory approval of new indications and therapies.
- Momentum in neuroscience and oncology portfolios.
Challenges Ahead
- Continued decline in Humira revenue.
- Aesthetics portfolio saw an 8.1% revenue drop.
- High milestone-related expenses impacted GAAP EPS.
- Tax rate increased significantly on a GAAP basis.
- International eye care and aesthetics sales declined.